RxDoctor Payments Data

Ashley Knable

Nurse Practitioner · Louisville, KYNPI 1851720577

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $82,526 of the $85,814 with a category attached, or 96.2%. AbbVie accounts for 82.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $30,856 and has fallen 66.3% since, to $10,391 in 2025. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,814in general payments, 2019–2025

Across 234 payments — averaging $366.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$71K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K
  • Biohaven Pharmaceuticals, Inc.$6K
  • Pfizer$69
  • Lilly USA, LLC$35
  • Amgen$21
  • plus $14 from 1 others

What the payments were for

  • Speaking & faculty fees$82,52696%
  • Travel & lodging$4301%
  • Food & beverage$2,8573%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,814 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$20,493
Medicare patients
116
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant289$373,779
Emgality PenGalcanezumab-Gnlm251$231,857
Nurtec OdtRimegepant Sulfate135$218,471
QuliptaAtogepant125$155,150
Aimovig AutoinjectorErenumab-Aooe162$138,208
Ajovy AutoinjectorFremanezumab-Vfrm73$67,671
Emgality SyringeGalcanezumab-Gnlm15$14,654
ZavzpretZavegepant Hcl12$13,482
Sumatriptan Succinate197$11,959
Naratriptan Hcl92$3,441
RizatriptanRizatriptan Benzoate131$2,811
Gabapentin142$2,167
Topiramate90$1,624
Eletriptan HbrEletriptan Hydrobromide14$971
Acetazolamide ErAcetazolamide11$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$70,681$528,930414 claims
PfizerNurtec Odt, Zavzpret$69$231,954147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →